Neovacs S.A. (EPA:ALNEV)

Market Cap	471.86K
Revenue (ttm)	433.94K
Net Income (ttm)	-32.91M
Shares Out	476.63K
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,574
Average Volume	2,736,101
Open	1.250
Previous Close	1.800
Day's Range	1.180 - 1.360
52-Week Range	0.280 - 260,000.000
Beta	-56.91
RSI	31.80
Earnings Date	Sep 4, 2025

About Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 20
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNEV

Financial Performance

In 2024, Neovacs's revenue was 433,937, a decrease of -18.65% compared to the previous year's 533,412. Losses were -32.91 million, 276.4% more than in 2023.